• Corpus ID: 26708976

Freireich's laws in the treatment of sarcomas.

@article{Benjamin1997FreireichsLI,
  title={Freireich's laws in the treatment of sarcomas.},
  author={Robert S. Benjamin},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 12 Pt 2},
  pages={
          2648-54
        }
}
  • R. Benjamin
  • Published 1 December 1997
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
In his Karnofsky lecture of May 6, 1976, Dr. Emil J Freireich formalized seven of his multiple laws ( 1 ). Although this manuscript will not deal with law 7, the Regulators Creed, laws 1-6 are relevant to the treatment of sarcomas (Table 1), and I shall address several areas emphasized by Dr. Freireich in that lecture: optimism, expertise, the importance of dose, and the need for individualized therapy. The first area is optimism. In his Kamofsky lecture, Dr. Freireich said, “If the clinical… 

Figures and Tables from this paper

Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89)
TLDR
The SCOS 89 yields a high event-free survival rate with reduced nephro-/neuro-/cardiotoxicity in patients with non-metastatic limb osteosarcoma, and this study evaluated the toxicity and outcome of a dose-intensive, high-dose 3- to 5-drug pilot protocol.
Summary of the first Emil J Freireich symposium.
  • R. Bast
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
The Freireich Symposiurn was M. D. Anderson Cancer Center (Houston, TX) at its best, with the faculty, fellows, staff, alumni, friends and the new President fully involved in the intellectual life of the institution.

References

SHOWING 1-10 OF 45 REFERENCES
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
TLDR
Future clinical trials will determine ifosfamide's role in combination chemotherapy and more clearly define the best schedule or schedules for the uroprotective administration of mesna.
Infusion Chemotherapy for Soft Tissue Sarcomas
TLDR
Patients who achieve complete remission have the potential for long term survival, and this is true whether the complete remission is a response to chemotherapy alone or to chemotherapy and surgery [7].
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of
Trends and variability in survival from osteosarcoma.
TLDR
In a study of patients first treated at the Mayo Clinic between Jan. 1, 1963, and July 1, 1974, the 3-year survival had become 50%, similar to that reported in connection with some of the new adjuvant therapies used in trials depending on historical controls.
Who took the clinical out of clinical research?--Mouse versus man: seventh David A Karnofsky Memorial Lecture--1976.
  • E. Freireich
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
The direction over the last 20 years has been unfavorable, but the predictions for the next millenium indicate a significant continuing improvement in the potential for reducing the impact of regulation of clinical cancer research.
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  • A. SantoroT. Tursz E. Rankin
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
TLDR
In advanced soft tissue sarcoma patients for whom significant tumor volume reduction may be an important end point of a chemotherapy regimen, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared.
Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
The regimen of doxorubicin (DOX), ifosfamide (IFF), and dacarbazine (DTIC) (AID) for previously untreated inoperable or metastatic sarcoma has acceptable toxicity with significant activity. Twenty
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
TLDR
Because of its substantial response in this phase II trial, the MAID regimen is being compared with doxorubicin and DTIC alone in advanced sarcoma and to observation in the adjuvant treatment of high-grade sarcomas in randomized trials.
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
  • K. AntmanJ. Crowley D. Trump
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
The response rate was higher for the ifosfamide-containing arm, significantly so in this and the ECOG studies, and an improved response rate may be particularly important for the preoperative management of high-grade, borderline resectable lesions or pulmonary metastases, particularly in younger patients.
Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response rate (including 10% complete responses) in 105 eligible adults with advanced sarcoma. The major dose-limiting toxicity
...
...